PlasmaTech Biopharmaceuticals, Inc. Announces Stock Ticker Symbol Change to PTBI
PR Newswire - Mon Nov 24, 7:30AM CST
PlasmaTech Biopharmaceuticals, Inc. announced today that FINRA has approved a change of Company's stock ticker symbol. Effective today, the Company's common shares will commence trading on the OTC Bulletin Board under the trading symbol "PTBI". The previous trading symbol was "ACCPD."
Stephen T. Sonis, DMD, DMSc Joins PlasmaTech Biopharmaceuticals' Scientific Advisory Board
PR Newswire - Tue Nov 04, 7:39AM CST
PlasmaTech Biopharmaceuticals, Inc. (OTCBB: ACCPD), a biopharmaceutical company advancing patient care in critical areas, announced that Stephen T. Sonis, DMD, DMSc has joined its Scientific Advisory Board (SAB). A world-renowned expert in the clinical treatment and research of cancer-related mucosal toxicities, Dr. Sonis has collaborated with management in recent years on advancing the company's clinical efforts of its oral mucositis treatment, MuGard.
PlasmaTech Biopharmaceuticals Appoints World Leading Plasma Experts to Scientific Advisory Board
PR Newswire - Wed Oct 29, 7:30AM CDT
PlasmaTech Biopharmaceuticals, Inc. (OTCBB: ACCPD), a biopharmaceutical company advancing patient care in critical areas, announced the appointment of leading experts to its newly formed scientific advisory board ("SAB"
PlasmaTech Biopharmaceuticals Signs Expanded MuGard Licensing Agreement With Norgine for Australia and New Zealand Territories
PR Newswire - Mon Oct 27, 7:40AM CDT
PlasmaTech Biopharmaceuticals, Inc. (OTCBB: ACCPD), a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand. The terms of the agreement are congruent to the Company's recent license with Norgine for MuGard in Europe. Norgine will now develop, manufacture, and commercialize MuGard in the new territories.
PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website
PR Newswire - Fri Oct 24, 7:30AM CDT
PlasmaTech Biopharmaceuticals, Inc. (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company advancing patient care in critical areas, announced it has implemented a 1-for-50 reverse split of its common stock effective at the opening of trading on Friday, October 24, 2014. PlasmaTech's common stock will trade on a split-adjusted basis under new CUSIP number 72754H109 and temporary ticker symbol "ACCPD". After 20 days, the common stock will commence trading under the ticker symbol (PTBI). In addition, the Company has changed its name to PlasmaTech Biopharmaceuticals, Inc. and launched its new corporate website: www.plasmatechbio.com.